PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“various FDA-approved and experimental PARP inhibitors have been shown to drive robust type I IFN secretion downstream of increased cytosolic availability of ssDNA or micronuclei (DNAcontaining structures generally formed by faulty mitoses) in a variety of tumors, including (but not limited to) BRCA1- and BRCA2-deficient neoplasms (Chabanon et al., 2019; Ding et al., 2018; Pantelidou et al., 2019;”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the administration of PARP inhibitors has been associated with PD-L1 upregulation in various cancer cells regardless of BRCA1/2 status, presumably as a consequence of type I IFN or IFNG signaling (Chabanon et al., 2019; Jiao et al., 2017; Sen et al., 2019; Shen et al., 2019).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chabanon et al., 2019
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 2×
“While various DDR defects have been shown to critically contribute to the accumulation of mutations in the tumor genome, only some of them have proven their predictive value as biomarkers of response to anti-PD-(L)1 therapy (6, 45).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundSelf-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
BackgroundGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 12×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundInfluentialGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 1×
“Other DNA repair defects, such as BRCA1/2 mutations have been found enriched in ICI responders (12).”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · cited 1×
“Both ERCC1 and BRCA1 defects confer sensitivity to platinum-based therapy (26, 27) and PARP inhibitors (PARPi) (28, 29), and while PARPi have demonstrated their efficacy in advanced BRCA-deficient breast cancers (30), these”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“However, a simple correlation between DNA repair defects-induced genomic instability, TMB and response to ICI cannot be claimed (5), as tumor heterogeneity (13) and other determinants of response also play a role that, importantly, seems to be independent from TMB in response to ICI (14, 15).”
BackgroundNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063 · cited 2×
“Very recent impressive results of large phase III trials in NSCLC have reported unprecedented improvements in overall survival and progression free survival when using anti-programmed death receptor 1 or -ligand 1 (anti-PD-(L)1) in first-line therapy (1, 2).”
Background
Research works printed but not linked: 1
- Robillard L. Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 PD-L1 inhibition in a syngenic BRCA2 mutant ovarian cancer model. Proceedings of the AACR. 2017;58(pt A):3650. Accessed January 7, 2019.
Cited by
Items 301–338 of 338
Faculty Opinions recommendation of Old dogs, new trick: classic cancer therapies activate cGAS.
Murray, B. W. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738147190.793586197
Chen, C., & Yang, L. (2023) · Research Square · doi:10.21203/rs.3.rs-2620356/v1
Chromatin regulators in DNA replication and genome stability maintenance during S-phase
Gospodinov, A. G., Dzhokova, S., Petrova, M., & Ugrinova, I. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.012
Wei, B., Xu, L., Guo, W., Wang, Y., Wu, J., Li, X., Cai, X., Hu, J., Wang, M., Xu, Q., et al. (2023) · doi:10.1158/0008-5472.c.6513226.v1
Data from PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer
Chabanon, R. M., Morel, D., Eychenne, T., Daage, L. C., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A. E., Duong-Ngo, C., et al. (2023) · doi:10.1158/0008-5472.c.6513481.v1
Self-citationFeng, Y., Liu, X., Xia, S., Li, Y., Li, P., Xiao, X., Han, Y., & Xia, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3426005/v1
Evolution of the Development of PARP Inhibitors
Plummer, R. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_1 · Cited by 1
Suppression of Homologous Recombination by RAD51 Functional Inactivation In Vivo in Mice
Matos-Rodrigues, G. E. (2020) · theses.fr (ABES) · doi:10.70675/6c3cf7f3za3a0z4ed4z97a2zeb1353824f3d
Yin, L., Qi, Y., & Jiang, Y. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-04948-w
“This correlation may be linked to the activation of immune response genes [5, 6].”
Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy
Gentile, F., Cros‐Perrial, E., & Jordheim, L. P. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189408
Nassief, G., Morecroft, R., Phillipps, J., Chen, D., & Ansstas, G. (2025) · Melanoma Management · doi:10.1080/20450885.2025.2598476
“…synthase-stimulator of interferon (cGas-stING) pathway, increasing cytokine levels, and stimulating interferon signaling in DDR-deficient cells [7]. additionally, paRpi was implicated in upregulating pD-L1 expression, increasing the tumor mutational burden, altering the tumor microenvironment,…”
Jiang, X., Li, Y., Zhang, N., Gao, Y., Han, L., Li, S., Li, J., Liu, X., Gong, Y., & Xie, C. (2021) · Figshare · doi:10.6084/m9.figshare.14429114
Zhu, J., Huang, R., Yang, R., Xiao, Y., Yan, J., Zheng, C., Xiao, W., Huang, C., & Wang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16800398
Saha, A., Zhao, S., Kindall, A., Wilder, C. S., Friedman, C. A., Clark, R., Georgiou, G., Stone, E., Kidane, D., & DiGiovanni, J. (2023) · Figshare · doi:10.6084/m9.figshare.22807626
Carvalho, S., Lopes, A. C., & Lopes, A. R. (2025) · Cureus · doi:10.7759/cureus.99473
“Although there is still no direct evidence that olaparib acts as a facilitator of paraneoplastic neurological syndromes, there is a hypothesis that it may modulate the immune response, potentially favouring the exacerbation of pre-existing autoimmune responses [3,10].”
Translational Aspects of DNA Damage Repair in Optimizing Cancer Chemotherapy
Lin, A., Jinyue, H., Jiang, A., Zhang, J., Cheng, Q., Zhang, H., Mao, W., & Luo, P. (2025) · Advanced Genetics · doi:10.1002/ggn2.202500036 · Cited by 1
Targeting DNA repair in lung cancer with PARP inhibitors
Buhler, A., & Pidgeon, G. P. (2025) · Academia oncology. · doi:10.20935/acadonco8089 · Cited by 1
Decade of Research on the cGAS-STING Pathway in Cancer: A Bibliometric Analysis (2015 – 2025)
Üren, N. (2026) · Gaziantep Islam Science and Technology University · doi:10.46871/eams.1779883
Modeling Hormone Receptor Positive Breast Cancer in Immunocompetent Mice
Pérez-Lanzón, M. (2021) · theses.fr (ABES) · doi:10.70675/8d0cd788z71c4z4627z898ezbb2b6500fa17
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Leveraging the replication stress response to optimize hepatocarcinoma therapy
Fang, J. (2024) · theses.fr (ABES) · doi:10.70675/e829496azb11ez4563zb5c8z74b7e8e8ff61
Ozmen, T. Y., Frankston, C. M., Rames, M. J., Ozmen, F., Yardımcı, G. G., & Mills, G. B. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2665447
“One potential rationale behind this combination therapy is that DNA damage in HRD tumors leads to the accumulation of neo-antigens, which can be processed and presented on MHC molecules to trigger an immune response that can be further amplified by ICBs [65,66].”
Identification of characteristic hub genes in the immune-active phase of chronic hepatitis B
Li, F., Li, Y., Du, Y., Fan, C., Xiong, J., Hu, F., Deng, X., Wang, X., Shi, H., Sun, X., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769749
Gan, S., Yang, S., Pan, J., & Wang, M. (2026) · Medicine · doi:10.1097/md.0000000000048775 · Cited by 1
Wu, T., Zhang, P., Xi, R., Shen, Y., Hu, L., Chang, S., Lu, J., Wang, G., & Wang, X. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105459
Deng, Q.-C., Kuang, W., Yang, Y.-J., Gong, C., Zhang, Y., Luo, Q., Luo, L., & Wang, G.-M. (2026) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s547154
A novel mechanism of autophagy-dependent immunosuppression in cancer?
Naulin, F., & Galluzzi, L. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.06.011
Myint, Z. W., Yan, D., Clair, W. H. S., Strup, S. E., Hensley, P. J., Allison, D. B., MARTIN, F. M., Kumar, R. N., Selene, I. I., Whitesell, A. N., et al. (2026) · JCO oncology advances. · doi:10.1200/oa-26-00039
Li, H., Xiang, M., Xu, Q., Liu, J., Jiao, X., Mu, W., Lv, X., Tao, K., Xu, Y., Zhou, D., et al. (2026) · Advanced Science · doi:10.1002/advs.76994
“…mechanism of PARP inhibition [ 54, 55 ], the immunomodulatory effects of PARP inhibitors and their contribution to antitumor efficacy are increasingly recognized [ 12, 13 ], providing a rationale for evaluating PARP inhibitors as TME-modulating agents even in HRD-negative models [ 11, 12, 56, 57 ].”
CD73 inhibition overcomes adaptive immune resistance to PARP inhibition in models of prostate cancer
Xie, P., Ma, R., Zhang, M., Fan, J., Tang, H., Song, L., Wan, Y., Kuzel, T. M., Fang, D., Cui, W., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci203785
Song, M., Wang, S., Fei, X., & Guo, G. (2026) · Virologica Sinica · doi:10.1016/j.virs.2026.08.014 · Cited by 1
Nondegradative ubiquitination organizes therapy-relevant stress assemblies
Ge, Y., Ni, H., Ye, M., & Jin, X. (2026) · Trends Open · doi:10.1016/j.treopn.2026.08.003
Miao, T., Zhao, J., Wu, J., Hou, J., Ma, T., & Wang, G. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2728335
“107,108 By contrast, ERCC1-proficient cells efficiently excised PARP1-associated lesions and repaired DSBs by HR, producing too few CCFs to activate the pathway.”
Monajjemi, M., Mollaamin, F., Haskılıç, Ş. Z., Madak, S. N., Yaman, A., Kabakoz, F. N., Çetinkaya, F. C., Özcan, B., Esenyel, B., Say, K., et al. (2026) · Biointerface Research in Applied Chemistry · doi:10.33263/briac165.128
“Several activations can be affected by perturbations in DNA structures, ultimately leading to the killing of the response action using poly ADP-ribose polymerase (PARP) [27,28], ataxia telangiectasia and rad3-related (ATR) inhibitors [29], as well as radiation [30].”
Karthikeyan, M. C., Viswanathan, Y., Dinakaran, P., Manivannan, S., & Arockiam, A. J. V. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02789-8
“PARP inhibitors generate cytosolic DNA fragments, activating cGAS–STING and T1IFN signaling and CCL5 secre - tion, thereby upregulating PD-L1 and recruiting T cells, particularly in ERCC1-deficient tumors [ 66].”
Chemical Modulation of the cGAS‐STING‐ENPP1 Axis: Medicinal Chemistry and Clinical Perspective
Shinde, A. U., & Bharate, S. B. (2026) · Medicinal Research Reviews · doi:10.1002/med.70118
Metadata
- Authors
- Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Cardeñosa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J.-C., Lord, C. J., & Postel-Vinay, S.
- Affiliations
- Université Paris-Sud (FR)
- Breast Cancer Now (GB)
- Institute of Cancer Research (GB)
- Inserm (FR)
- Sage Bionetworks (US)
- King's College London (GB)
- University of California, San Francisco (US)
- ORCID
- Chabanon, Roman M.
- Krastev, Dragomir B.
- Adam, Julien
- Morel, Daphné
- Garrido, Marlène
- Lamb, Andrew
- Dorvault, Nicolas
- Rouanne, Mathieu
- Marlow, Rebecca
- Bajrami, Ilirjana
- Besse, Benjamin
- Ashworth, Alan
- Pettitt, Stephen J.
- Haider, Syed
- Marabelle, Aurélien
- Tutt, Andrew N.J.
- Soria, Jean-Charles
- Lord, Christopher J.
- Postel-Vinay, Sophie
- Venue
- Journal of Clinical Investigation
- Published
- 2019-02-11
- Volume
- 129
- Issue
- 3
- Pages
- 1211-1228
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6391116
- OpenAlex
- W2908418801
- Cited by
- 332
- References
- 62
- Citations by year
- 2026: 31 · 2025: 36 · 2024: 39 · 2023: 45 · 2022: 43 · 2021: 61 · 2020: 54 · 2019: 22
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- AstraZeneca
- Sanofi
- Merck KGaA
- Les Laboratories Pierre Fabre
- Fondation Philanthropia
- Cancer Research UK (14276, 25237, 24439)
- Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
- Institut National Du Cancer (INCa-DGOS-INSERM-12551)
- Institut Gustave-Roussy
- Direction Générale de l’offre de Soins
- Servier
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- PARP inhibitors, non-small cell lung cancer, triple-negative breast cancer, cGAS-STING pathway, cytosolic DNA sensing, type I interferon, PARP1, micronuclei, RANTES, PD-L1 expression, lymphocyte infiltration, olaparib, rucaparib, DNA repair deficiency
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, A549 Cells, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Endonucleases, Female, Humans, Interferon-gamma, Lung Neoplasms, Membrane Proteins, Nucleotidyltransferases, BRCA1 Protein, B7-H1 Antigen, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.